AUPHOS, A “FIRST-IN CLASS” ORAL AGENT FOR CORRECTING METABOLIC DYSFUNCTION IN IBD

Mucosal repair is the goal of medical therapy in IBD. Prospective inception cohort pediatric studies suggest that suppression of mitochondrial genes lead to unfavorable clinical outcomes in ulcerative colitis (UC) and Crohn’s disease (CD). We posit that the inability to restore epithelial mitochondrial respiration impairs ulcer healing in IBD. In the current study, we tested whether a novel compound (AuPhos) that improves mitochondrial function promotes ulcer healing in IBD.

This entry was posted in News. Bookmark the permalink.